| Description | • A unique collection of 3010 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS)•Drug repurposing, the application of known drugs to treat new disease indication, holds potential of• A unique collection of 3010 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS)•Drug repurposing, the application of known drugs to treat new disease indication, holds potential of rapid clinical impact at a lower cost than de novo drug development• Safety confirmed by clinical phase 1• Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc• Structurally diverse, medicinally active, and cell permeable.• Rich documentation with structure, IC50, and customer reviews• NMR and HPLC validated to ensure the highest purityProduct DetailsFormulation 2678 compounds pre-dissolved in 10mM DMSO,244 compounds pre-dissolved in 10mM H2O,72 compounds pre-dissolved in 2mM DMSO,16 compounds pre-dissolved in 2mM H2O Container 96 Well Format Sample Storage Tube With Screw Cap and Optional 2D BarcodeStability 12 months -20°C in DMSO24 months -80°C in DMSOFDA-approved & Passed Phase I Drug Library Composition... Read More | The content of this cell is too long for an XLSX file (more than 32767 characters). Please use the CSV format for this export | Inquire | MAP kinase substrate (MBP) is a peptide substrate for ERK 1 and ERK 2 MAP kinases. Sequence contains amino acids 95-98 of myelin basic protein (MBP) including Thr 97 within the Pro-X-Ser/Thr-Pro MAP kinase substrate consensus sequence phosphorylation site.MAP kinase substrate (MBP)is a peptide MAP kinase substrate (MBP) is a peptide substrate for ERK 1 and ERK 2 MAP kinases. Sequence contains amino acids 95-98 of myelin basic protein (MBP) including Thr 97 within the Pro-X-Ser/Thr-Pro MAP kinase substrate consensus sequence phosphorylation site.MAP kinase substrate (MBP)is a peptide substrate for ERK 1 and ERK 2 MAP kinases... Read More | Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor ( IC 50 s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor ( IC 50 s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a colorectal xenograft modelIn VitroTankyrase-IN-2 (1-10000 nM; 24 hours) leads to a dose-dependent increase of tankyrase protein abundance with an EC 50 of 320 nM in DLD1 cells. This is in the same potency range as the value for axin2 increase (EC 50 =319 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.IC50& Target:IC50: 10 nM (TNKS1), 7 nM (TNKS2), 710 nM (PARP1)... Read More |